Literature DB >> 9808522

Increased sensitivity for detection of micrometastases in bone-marrow/peripheral-blood stem-cell products from breast-cancer patients by negative immunomagnetic separation.

B Naume1, E Borgen, J M Nesland, K Beiske, E Gilen, A Renolen, G Ravnås, H Qvist, R Kåresen, G Kvalheim.   

Abstract

Immunocytochemical detection (ICC) of isolated tumor cells in bone marrow (BM) is currently the most established method for monitoring early dissemination in epithelial cancer. However, the low sample size that can practically be analyzed restricts the sensitivity and reliability of the ICC method. To be able to analyze larger samples, a negative immunomagnetic separation (IMS) technique, utilising anti-CD45-conjugated Dynabeads, has been developed. Tumor-cell enrichment by depletion of CD45-expressing mononuclear cells (MNC) is followed by ICC for detection of the cytokeratin (CK)-positive (+) epithelial cells. In this study, bone-marrow samples (n = 165) and peripheral-blood-progenitor-cell (PBPC) apheresis products (n = 22) from breast-cancer patients were analyzed. The negative IMS analysis of 1 to 2 x 10(7) MNC was compared with ICC analysis of 2 x 10(6) unseparated MNC. Negative IMS resulted in 85% mean depletion of MNC. The results showed that 11.7% of the samples were positive by ICC analysis of unseparated MNC, as compared with 23.5% after negative IMS. In samples presenting > 10 CK+ cells, a 4-fold higher number of positive cells was detected by the negative IMS technique. Moreover, there was no evidence for general enrichment of false-positive cells. Altogether our results show that negative IMS is an efficient enrichment method for sensitive detection of CK+ cells in BM/PBPC products from breast-cancer patients. This opens the possibility for further characterization of micrometastatic tumor cells.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9808522     DOI: 10.1002/(sici)1097-0215(19981123)78:5<556::aid-ijc5>3.0.co;2-g

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  12 in total

1.  Transcriptional complementarity in breast cancer: application to detection of circulating tumor cells.

Authors:  R L Houghton; D C Dillon; D A Molesh; B K Zehentner; J Xu; J Jiang; C Schmidt; A Frudakis; E Repasky; A Maltez Filho; M Nolasco; R Badaro; X Zhang; P C Roche; D H Persing; S G Reed
Journal:  Mol Diagn       Date:  2001-06

2.  Chemokine receptor CXCR4 expression in breast cancer as a potential predictive marker of isolated tumor cells in bone marrow.

Authors:  Neslihan Cabioglu; Aysegul Sahin; Michele Doucet; Ekrem Yavuz; Abdullah Igci; Engin O Yildirim; Esin Aktas; Sema Bilgic; Bayram Kiran; Gunnur Deniz; Janet E Price
Journal:  Clin Exp Metastasis       Date:  2005       Impact factor: 5.150

3.  Sensitive fluorescent in situ hybridisation method for the characterisation of breast cancer cells in bone marrow aspirates.

Authors:  A Forus; H K Høifødt; G E Overli; O Myklebost; O Fodstad
Journal:  Mol Pathol       Date:  1999-04

4.  A rare-cell detector for cancer.

Authors:  Robert T Krivacic; Andras Ladanyi; Douglas N Curry; H B Hsieh; Peter Kuhn; Danielle E Bergsrud; Jane F Kepros; Todd Barbera; Michael Y Ho; Lan Bo Chen; Richard A Lerner; Richard H Bruce
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-12       Impact factor: 11.205

5.  Immunomagnetic enrichment of disseminated tumor cells in bone marrow and blood of breast cancer patients by the Thomsen-Friedenreich-Antigen.

Authors:  Christian Schindlbeck; Julia Stellwagen; Udo Jeschke; Uwe Karsten; Brigitte Rack; Wolfgang Janni; Julia Jückstock; Augustinos Tulusan; Harald Sommer; Klaus Friese
Journal:  Clin Exp Metastasis       Date:  2008-01-10       Impact factor: 5.150

Review 6.  Disseminated and circulating tumor cells in bone marrow and blood of breast cancer patients: properties, enrichment, and potential targets.

Authors:  C Schindlbeck; U Andergassen; J Jueckstock; B Rack; W Janni; U Jeschke
Journal:  J Cancer Res Clin Oncol       Date:  2016-01-29       Impact factor: 4.553

7.  Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients.

Authors:  Galatea Kallergi; Maria A Papadaki; Eleni Politaki; Dimitris Mavroudis; Vassilis Georgoulias; Sophia Agelaki
Journal:  Breast Cancer Res       Date:  2011-06-10       Impact factor: 6.466

8.  Circulating tumor cells measurements in hepatocellular carcinoma.

Authors:  Franck Chiappini
Journal:  Int J Hepatol       Date:  2012-05-28

9.  Screening and identification of differentially expressed transcripts in circulating cells of prostate cancer patients using suppression subtractive hybridization.

Authors:  Xin Li; Carson Wong; Ralph Mysel; Gennady Slobodov; Adam Metwalli; Jarrett Kruska; C Scott Manatt; Daniel J Culkin; Bradley P Kropp; Hsueh-Kung Lin
Journal:  Mol Cancer       Date:  2005-08-08       Impact factor: 27.401

10.  Hypoxia-inducible factor-1alpha and vascular endothelial growth factor expression in circulating tumor cells of breast cancer patients.

Authors:  Galatea Kallergi; Harris Markomanolaki; Vicky Giannoukaraki; Maria A Papadaki; Areti Strati; Evi S Lianidou; Vassilis Georgoulias; Dimitris Mavroudis; Sofia Agelaki
Journal:  Breast Cancer Res       Date:  2009-11-17       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.